STOCK TITAN

VolitionRx (NYSE: VNRX) issues stock to Lind for note repayments

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

VolitionRx Limited reported unregistered sales of common stock tied to a previously issued senior secured convertible promissory note. The company had issued a note with an original principal amount of $7,500,000 to Lind Global Asset Management XII LLC under a securities purchase agreement.

To satisfy repayment obligations under this note, VolitionRx issued 333,332 shares of common stock to Lind on June 17, 2026 for a $416,666 payment obligation and 212,259 shares on May 19, 2026 for another $416,666 obligation. The transactions were made to an existing securityholder, without commissions, as private placements relying on exemptions from registration under the Securities Act and state blue sky laws.

Positive

  • None.

Negative

  • None.
Item 3.02 Unregistered Sales of Equity Securities Securities
The company sold equity securities in a private placement or other unregistered transaction.
Note principal $7,500,000 Original principal amount of senior secured convertible promissory note to Lind
June 17, 2026 shares issued 333,332 shares Common stock issued to Lind to satisfy a $416,666 obligation
June 17, 2026 payment obligation $416,666 Obligation satisfied via issuance of 333,332 shares to Lind
May 19, 2026 shares issued 212,259 shares Common stock issued to Lind to satisfy a $416,666 obligation
May 19, 2026 payment obligation $416,666 Obligation satisfied via issuance of 212,259 shares to Lind
senior secured convertible promissory note financial
"issued to Lind ... a senior secured convertible promissory note in the original principal amount"
A senior secured convertible promissory note is a formal IOU a company issues that is backed by specific assets (secured), given higher priority for repayment than other debts (senior), and can be exchanged for company shares instead of cash (convertible). For investors this means the loan is safer than unsecured debt because it has collateral and repayment priority, but it also carries the potential for dilution if the lender converts the note into equity — like holding a mortgage-backed IOU that can later be swapped for ownership stakes.
Section 3(a)(9) regulatory
"in reliance on the exemption afforded by Section 3(a)(9) or alternatively Section 4(a)(2)"
Section 3(a)(9) is a provision of U.S. securities law that exempts certain exchanges of an issuer’s own securities with its existing holders from the usual public registration rules, typically when the swap doesn’t involve a public offering or outside buyers. For investors, it matters because such exchanges can change who holds what, affect dilution and liquidity, and may occur with less public disclosure than a registered sale — think of it like swapping old coupons for new ones behind the scenes rather than selling them in a public marketplace.
Section 4(a)(2) regulatory
"in reliance on the exemption afforded by Section 3(a)(9) or alternatively Section 4(a)(2)"
Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.
Rule 506 of Regulation D regulatory
"and/or Rule 506 of Regulation D under the Securities Act"
Rule 506 of Regulation D is a U.S. Securities and Exchange Commission exemption that lets companies sell securities privately without registering them with the SEC, similar to a private party invitation rather than a public auction. It matters to investors because it determines how much information they’ll receive, who can buy (accredited vs. non-accredited), whether public advertising is allowed, and how easily the investment can be resold — all factors that affect risk, transparency and liquidity.
blue sky laws regulatory
"and corresponding provisions of state securities or “blue sky” laws"
State-level securities laws that require companies and investment products to register, disclose key information, or meet exemptions before being sold to residents; they act like local consumer protection rules for investments. They matter to investors because they reduce the risk of fraud, ensure basic disclosure about what is being offered, and can affect where and how easily an investment can be bought or sold—similar to how building codes affect whether a house can be advertised in a neighborhood.
Unregistered Sales of Equity Securities regulatory
"Item 3.02 Unregistered Sales of Equity Securities"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): June 17, 2026

 

VolitionRx Limited

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-36833

 

91-1949078

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of Incorporation)

 

File Number)

 

Identification Number)

 

1489 West Warm Springs Road, Suite 110

Henderson, Nevada 89014

(Address of principal executive offices and zip code)

 

+1 (512) 774-8930

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed from last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

Trading Symbol(s)

 

Name of Each Exchange on which Registered

Common Stock, par value $0.001 per share

 

VNRX

 

NYSE American, LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 3.02 Unregistered Sales of Equity Securities

 

As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Global Asset Management XII LLC, a Delaware limited liability company (“Lind”), a senior secured convertible promissory note in the original principal amount of $7,500,000. In connection with its repayment obligations under such note, (a) on June 17, 2026, the Company issued to Lind an aggregate of 333,332 shares of common stock to satisfy a $416,666 payment obligation, and (b) on May 19, 2026, the Company issued to Lind an aggregate of 212,259 shares of common stock to satisfy a $416,666 payment obligation. The offering and sale of the shares of common stock underlying the note was made in reliance on the exemption afforded by Section 3(a)(9) or alternatively Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Rule 506 of Regulation D under the Securities Act, and corresponding provisions of state securities or “blue sky” laws. The issuance of the shares of common stock was to an existing securityholder, did not involve any paid commissions, did not involve a public offering and was made without general solicitation or general advertising.

 

2

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

VOLITIONRX LIMITED

 

 

 

 

Date: June 18, 2026

By:  

/s/ Cameron Reynolds

 

 

 

Cameron Reynolds

 

 

 

Chief Executive Officer & President

 

 

 
3

 

 

FAQ

What unregistered share issuances did VolitionRx (VNRX) disclose?

VolitionRx disclosed issuing 333,332 shares on June 17, 2026 and 212,259 shares on May 19, 2026. Both issuances were to Lind Global Asset Management XII LLC to satisfy two separate $416,666 repayment obligations under a senior secured convertible promissory note.

Why did VolitionRx (VNRX) issue shares to Lind Global Asset Management XII LLC?

VolitionRx issued shares to Lind to satisfy repayment obligations under a senior secured convertible promissory note with an original principal of $7,500,000. The June and May 2026 share issuances each corresponded to a $416,666 payment obligation owed under that note.

What securities law exemptions did VolitionRx (VNRX) rely on for these share issuances?

The company relied on exemptions under Section 3(a)(9) or alternatively Section 4(a)(2) of the Securities Act, and/or Rule 506 of Regulation D. Corresponding state securities or blue sky law exemptions were also referenced for these private, unregistered equity transactions.

Were VolitionRx’s June and May 2026 share issuances public offerings?

No, the issuances were not public offerings. VolitionRx stated the shares were issued to an existing securityholder, involved no paid commissions, and were completed without general solicitation or general advertising, consistent with private placement exemptions under federal and state securities laws.

How many VolitionRx (VNRX) shares were issued on June 17, 2026 and what obligation did they satisfy?

On June 17, 2026, VolitionRx issued 333,332 shares of common stock to Lind Global Asset Management XII LLC. These shares were issued to satisfy a specific $416,666 repayment obligation under the company’s previously issued senior secured convertible promissory note.

How many VolitionRx (VNRX) shares were issued on May 19, 2026 and what obligation did they satisfy?

On May 19, 2026, VolitionRx issued 212,259 shares of common stock to Lind Global Asset Management XII LLC. This issuance was used to satisfy a separate $416,666 payment obligation under the same senior secured convertible promissory note originally issued for $7,500,000.

Filing Exhibits & Attachments

5 documents